188 related articles for article (PubMed ID: 31319379)
1. Why don't corticotroph tumors always produce Cushing's disease?
García-Martínez A; Cano DA; Flores-Martínez A; Gil J; Puig-Domingo M; Webb SM; Soto-Moreno A; Picó A
Eur J Endocrinol; 2019 Sep; 181(3):351-361. PubMed ID: 31319379
[TBL] [Abstract][Full Text] [Related]
2. The expression of glucocorticoid and mineralocorticoid receptors in pituitary tumors causing Cushing's disease and silent corticotroph tumors.
Kober P; Rusetska N; Mossakowska BJ; Maksymowicz M; Pękul M; Zieliński G; Styk A; Kunicki J; Działach Ł; Witek P; Bujko M
Front Endocrinol (Lausanne); 2023; 14():1124646. PubMed ID: 37065760
[TBL] [Abstract][Full Text] [Related]
3. In situ hybridization study of pro-opiomelanocortin (POMC) gene expression in human pituitary corticotrophs and their adenomas.
Stefaneanu L; Kovacs K; Horvath E; Lloyd RV
Virchows Arch A Pathol Anat Histopathol; 1991; 419(2):107-13. PubMed ID: 1651583
[TBL] [Abstract][Full Text] [Related]
4. Expression of genes related to corticotropin production and glucocorticoid feedback in corticotroph adenomas of dogs with Cushing's disease.
Teshima T; Hara Y; Takekoshi S; Teramoto A; Osamura RY; Tagawa M
Domest Anim Endocrinol; 2009 Jan; 36(1):3-12. PubMed ID: 18818046
[TBL] [Abstract][Full Text] [Related]
5. Inhibitory effects of SOM230 on adrenocorticotropic hormone production and corticotroph tumor cell proliferation in vitro and in vivo.
Murasawa S; Kageyama K; Sugiyama A; Ishigame N; Niioka K; Suda T; Daimon M
Mol Cell Endocrinol; 2014 Aug; 394(1-2):37-46. PubMed ID: 25011056
[TBL] [Abstract][Full Text] [Related]
6. Significance of absent prohormone convertase 1/3 in inducing clinically silent corticotroph pituitary adenoma of subtype I--immunohistochemical study.
Ohta S; Nishizawa S; Oki Y; Yokoyama T; Namba H
Pituitary; 2002; 5(4):221-3. PubMed ID: 14558669
[TBL] [Abstract][Full Text] [Related]
7. Differential gene expression in ACTH -secreting and non-functioning pituitary tumors.
Tateno T; Izumiyama H; Doi M; Yoshimoto T; Shichiri M; Inoshita N; Oyama K; Yamada S; Hirata Y
Eur J Endocrinol; 2007 Dec; 157(6):717-24. PubMed ID: 18057378
[TBL] [Abstract][Full Text] [Related]
8. Two Distinctive POMC Promoters Modify Gene Expression in Cushing Disease.
Araki T; Tone Y; Yamamoto M; Kameda H; Ben-Shlomo A; Yamada S; Takeshita A; Yamamoto M; Kawakami Y; Tone M; Melmed S
J Clin Endocrinol Metab; 2021 Aug; 106(9):e3346-e3363. PubMed ID: 34061962
[TBL] [Abstract][Full Text] [Related]
9. Cyclin E-Mediated Human Proopiomelanocortin Regulation as a Therapeutic Target for Cushing Disease.
Liu NA; Araki T; Cuevas-Ramos D; Hong J; Ben-Shlomo A; Tone Y; Tone M; Melmed S
J Clin Endocrinol Metab; 2015 Jul; 100(7):2557-64. PubMed ID: 25942479
[TBL] [Abstract][Full Text] [Related]
10. Targeting the ERK pathway for the treatment of Cushing's disease.
Zhang D; Bergsneider M; Wang MB; Heaney AP
Oncotarget; 2016 Oct; 7(43):69149-69158. PubMed ID: 27708250
[TBL] [Abstract][Full Text] [Related]
11. Relevance of mutations in protein deubiquitinases genes and
Pękul M; Szczepaniak M; Kober P; Rusetska N; Mossakowska BJ; Baluszek S; Kowalik A; Maksymowicz M; Zieliński G; Kunicki J; Witek P; Bujko M
Front Endocrinol (Lausanne); 2024; 15():1302667. PubMed ID: 38487343
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical properties of silent corticotroph adenoma and Cushing's disease.
Iino K; Oki Y; Matsushita F; Yamashita M; Hayashi C; Miura K; Nishizawa S; Nakamura H
Pituitary; 2007; 10(1):35-45. PubMed ID: 17410413
[TBL] [Abstract][Full Text] [Related]
13. Aberrant Nuclear Translocation of E2F1 and Its Association in Cushing's Disease.
Araki T; Wang J; Lawrence R; Kawakami Y
Endocrinology; 2022 Aug; 163(8):. PubMed ID: 35678423
[TBL] [Abstract][Full Text] [Related]
14. Pro-opiomelanocortin gene expression in silent corticotroph-cell adenoma and Cushing's disease.
Nagaya T; Seo H; Kuwayama A; Sakurai T; Tsukamoto N; Nakane T; Sugita K; Matsui N
J Neurosurg; 1990 Feb; 72(2):262-7. PubMed ID: 2153197
[TBL] [Abstract][Full Text] [Related]
15. Clinical, hormonal and molecular characterization of pituitary ACTH adenomas without (silent corticotroph adenomas) and with Cushing's disease.
Raverot G; Wierinckx A; Jouanneau E; Auger C; Borson-Chazot F; Lachuer J; Pugeat M; Trouillas J
Eur J Endocrinol; 2010 Jul; 163(1):35-43. PubMed ID: 20385723
[TBL] [Abstract][Full Text] [Related]
16. Comparison of ACTH secretion in Cushing's adenoma and clinically silent corticotroph adenoma by cell immunoblot assay.
Kojima Y; Suzuki S; Yamamura K; Ohhashi G; Yamamoto I
Endocr J; 2002 Jun; 49(3):285-92. PubMed ID: 12201210
[TBL] [Abstract][Full Text] [Related]
17. Cold inducible RNA binding protein upregulation in pituitary corticotroph adenoma induces corticotroph cell proliferation via Erk signaling pathway.
Jian F; Chen Y; Ning G; Fu W; Tang H; Chen X; Zhao Y; Zheng L; Pan S; Wang W; Bian L; Sun Q
Oncotarget; 2016 Feb; 7(8):9175-87. PubMed ID: 26824322
[TBL] [Abstract][Full Text] [Related]
18. Nur77 gene expression levels were involved in different ACTH-secretion autonomy between Cushing's disease and subclinical Cushing's disease.
Tabuchi Y; Kitamura T; Fukuhara A; Mukai K; Onodera T; Miyata Y; Hamasaki T; Oshino S; Saitoh Y; Morii E; Otsuki M; Shimomura I
Endocr J; 2016 Jun; 63(6):545-54. PubMed ID: 27025408
[TBL] [Abstract][Full Text] [Related]
19. Proopiomelanocortin processing and prohormone convertase 1 level in dogs with pituitary corticotroph tumors.
Benchekroun G; de Fornel-Thibaud P; Rosenberg D
Domest Anim Endocrinol; 2018 Jan; 62():83-87. PubMed ID: 29145000
[TBL] [Abstract][Full Text] [Related]
20. Single-cell RNA sequencing in silent corticotroph tumors confirms impaired POMC processing and provides new insights into their invasive behavior.
Zhang D; Hugo W; Bergsneider M; Wang MB; Kim W; Vinters HV; Heaney AP
Eur J Endocrinol; 2022 May; 187(1):49-64. PubMed ID: 35521707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
